This article is more than 5 years old. Information may no longer be current.
Increased doses of dulaglutide may lower HbA1c more effectively
Click Here to Manage Email Alerts
A weekly dose of 3 mg or 4.5 mg dulaglutide combined with metformin proved superior to a 1.5-mg dose in lowering HbA1c levels during the AWARD-11 trial, according to a press release from Eli Lilly and Co.
Besides HbA1c reduction, the company stated that those taking higher doses of dulaglutide (Trulicity) lost more weight without experiencing more frequent reductions in safety or tolerability compared with those taking lower doses.
These initial results from the phase 3 AWARD-11 trial, which randomly assigned 1,842 participants with type 2 diabetes to one of the three dosages, are based on 36 weeks of data, the release stated. Additional results of the entire 52-week trial will be available later this year, according to the company.
“Diabetes is a progressive condition, which is why people may need to adjust their treatment to achieve further glycemic control,” Brad Woodward, MD, global development leader of incretins at Eli Lilly, said in the release. “Lilly chose to study additional doses of dulaglutide to provide more options for clinicians and people living with type 2 diabetes. We’re encouraged by the superior results, which showed a significant reduction in [HbA1c] beyond the effective Trulicity doses already available.”
As Endocrine Today previously reported, dulaglutide has shown effective results in lowering cardiovascular and renal complications and can even limit the loss of kidney function in those with chronic kidney disease.